share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K:諾和諾德-股票回購計劃
美股SEC公告 ·  08/26 10:46

Moomoo AI 已提取核心訊息

Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program on August 26, 2024. The program, which began on February 6, 2024, aims to repurchase up to DKK 20 billion worth of shares over a 12-month period. As part of this initiative, a specific share repurchase plan was initiated on August 7, 2024, targeting the repurchase of B shares for an amount up to DKK 2.4 billion, to be completed by November 4, 2024. Since the last update on August 19, 2024, Novo Nordisk has acquired an additional 205,000 B shares at an average price of approximately DKK 914.16, amounting to a transaction value of DKK 187,386,081. This brings the total repurchased under the program to 540,187 B shares, with an accumulated transaction value of DKK 485,999,068. The company...Show More
Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program on August 26, 2024. The program, which began on February 6, 2024, aims to repurchase up to DKK 20 billion worth of shares over a 12-month period. As part of this initiative, a specific share repurchase plan was initiated on August 7, 2024, targeting the repurchase of B shares for an amount up to DKK 2.4 billion, to be completed by November 4, 2024. Since the last update on August 19, 2024, Novo Nordisk has acquired an additional 205,000 B shares at an average price of approximately DKK 914.16, amounting to a transaction value of DKK 187,386,081. This brings the total repurchased under the program to 540,187 B shares, with an accumulated transaction value of DKK 485,999,068. The company now holds 12,935,944 B shares as treasury shares, which is 0.3% of the share capital. The total number of A and B shares, including treasury shares, is 4,465,000,000. Since the start of the repurchase program, Novo Nordisk has bought back 11,607,313 B shares at an average price of DKK 879.94 per share, totaling DKK 10,213,705,118. Novo Nordisk is committed to defeating serious chronic diseases and employs approximately 69,000 people across 80 countries.
諾和諾德(Novo Nordisk A/S)是一家領先的全球醫藥健康公司,在2024年8月26日宣佈了其回購計劃的進展。該計劃始於2024年2月6日,旨在在12個月內回購價值200億丹麥克朗的股份。作爲該計劃的一部分,於2024年8月7日啓動了特定的股份回購計劃,目標是回購B股,金額高達24億丹麥克朗,將於2024年11月4日前完成。自2024年8月19日最後更新以來,諾和諾德以平均價格約爲914.16丹麥克朗的價格收購了額外的2050000億股,交易金額爲187,386,081丹麥克朗。這使得該計劃下回購的股票總數達到5401870億股,累計交易金額爲485,999,068丹麥克朗。公司現持...展開全部
諾和諾德(Novo Nordisk A/S)是一家領先的全球醫藥健康公司,在2024年8月26日宣佈了其回購計劃的進展。該計劃始於2024年2月6日,旨在在12個月內回購價值200億丹麥克朗的股份。作爲該計劃的一部分,於2024年8月7日啓動了特定的股份回購計劃,目標是回購B股,金額高達24億丹麥克朗,將於2024年11月4日前完成。自2024年8月19日最後更新以來,諾和諾德以平均價格約爲914.16丹麥克朗的價格收購了額外的2050000億股,交易金額爲187,386,081丹麥克朗。這使得該計劃下回購的股票總數達到5401870億股,累計交易金額爲485,999,068丹麥克朗。公司現持有129359440億股作爲庫藏股,佔股本的0.3%。A股和B股的總股本,包括庫藏股,爲4,465,000,000股。自回購計劃開始以來,諾和諾德以平均價格879.94丹麥克朗每股回購了116073130億股,總額爲10,213,705,118丹麥克朗。諾和諾德致力於戰勝嚴重的慢性疾病,公司在80個國家擁有約69,000名員工。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息